Frontlight ResearchEarly access
CompletedEarly phase 1
Carboprost (Hemabate) for Fibroid Resection
Key facts
- Who runs it
- Northwestern University
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 19 people enrolled
- Started
- 12 Jul 2022
- Ended
- 6 May 2024
- Type of study
- Interventional
- Treatments tested
- Carboprost Tromethamine
- Record updated
- 19 September 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients scheduled to undergo myomectomy with a surgeon in the division of Minimally Invasive Gynecologic Surgery
- Ability to understand and the willingness to sign a written informed consent
Who cannot take part
- If any oxytocic agents have been or will be administered prior to surgery
- History of renal and/or hepatic impairment
- Active cardiac disease, pulmonary disease, or pelvic inflammatory disease (PID)
- Anemia (Hgb < 7g/dL), diabetes mellitus, jaundice, or epilepsy
Where in United States
- Northwestern University - Northwestern Medicine, Lavin Family PavilionChicago, United States
About the trial
What the trial wants to find out
The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
The group in the trial
- HemabateTreatment being tested
Dilute the 250mcg/mL vial with 25mL saline to create a solution of 10mcg/mL, and inject no more than 10mL of diluted solution at the base of the fibroid. The route of administration depends on the location of the fibroid.
Treatment: Carboprost Tromethamine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Carboprost Tromethamine (Hemabate) for Resection of Fibroids-a Pilot Study
- Publications
- Prostaglandin Injection for Myoma Expulsion (PRIME): Case Series of a Novel Approach to Hysteroscopic Resection of FIGO Type 2 Myomas.Journal of minimally invasive gynecology, 2024
- Record updated
- 19 September 2024